Erythropoietin Drugs Market By Drug Class (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa), By Drug Type (Biologics, Biosimilar), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Cancer, Renal Disease, Hematology, Neurology), Industry Trends, Estimation & Forecast, 2018 - 2025

Check Today's Best Price

$3500 Buy Now
Erythropoietin Drugs Market is expected to grow with a CAGR of 7% during the forecast period of 2018 to 2025
  • Market Overview:

    Erythropoietin (EPO), also known as hematopoietin, is a glycoprotein hormone produced by kidneys, responsible for stimulating the bone marrow to produce red blood cells within the body. Erythropoietin drugs market is witnessing an impressive growth with the increasing prevalence of anemia among women, especially in the developing and under developed countries such as India, Nigeria and many others. Moreover, rising number of patients suffering from chronic diseases such as cancer and chronic kidney disease is another factor which is driving the market growth. According to American Cancer Society, in 2018, 1,735,350 new cancer cases are anticipated to be diagnosed. In addition to this, patent expiration of the branded drugs lets the generic and biosimilar manufacturers to enter the market. These drugs are cheap, and hence are affordable for every economic group of the society.

    Additionally, reimbursement policies for patients is yet another factor responsible for the growth of erythropoietin drugs market. However, side effects of erythropoietin drugs is creating hesitation among the patients to adopt these drugs, thus, hampering the growth of the erythropoietin drugs market. On the other hand, favorable government initiatives in order to promote the usage of generic drugs can put forward a lucrative growth platform for the drug manufacturers involved in generic drugs. For example, the U.S. Food and Drug Administration has recently approved Retacrit (epoetin alfa-epbx) as a drug biosimilar to Epogen/Procrit (epoetin alfa) from Amgen Inc, to treat anemia caused by chronic kidney disease, chemotherapy. It is also approved to be used before and after the surgeries causing excessive blood loss, as it reduces the chances of red blood cell transfusion.

    The report provides detailed qualitative and quantitative analysis of the Erythropoietin Drugs market. Market size and forecast in terms of value and volume has been provided for the period – (2017 – 2025), for the segments namely drug class, drug type, distribution channel, application in each of the major regions.

    Erythropoietin Drugs Market Segmentation

    By Drug Class
    • Epoetin-alfa
    • Epoetin-beta
    • Darbepoetin-alfa

    By Drug Type
    • Biologics
    • Biosimilar

    By Distribution Channel 
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

    By Application
    • Cancer
    • Renal Disease
    • Hematology
    • Neurology
    • Others

    By geography

    • North America
    o U.S.
    o Canada
    o Mexico

    • Europe
    o U.K.
    o France
    o Germany
    o Italy
    o Spain
    o Rest of Europe

    • Asia-Pacific
    o China
    o Japan
    o India
    o Korea
    o Rest of APAC

    • South America
    o Brazil
    o Rest of South America

    • Rest of the World
    o Middle East
    o Africa

    keyboard_arrow_up
  • CHAPTER 1. INTRODUCTION
    1.1. RESEARCH METHODOLOGY
    1.1.1. ERC DESK RESEARCH
    1.1.2. ERC DATA SYNTHESIS
    1.1.3. DATA VALIDATION AND MARKET FEEDBACK
    1.1.4. ERC DATA SOURCES

    CHAPTER 2. ERYTHROPOIETIN DRUGS MARKET OVERVIEW
    2.1. ERYTHROPOIETIN DRUGS MARKET INTRODUCTION
    2.2. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    2.2.1. GLOBAL ERYTHROPOIETIN DRUGS PRODUCTION (VOLUME) AND GROWTH RATE (%), (2017-2025)
    2.3. GLOBAL ERYTHROPOIETIN DRUGS MARKET CAPACITY AND GROWTH RATE, 2017-2025
    2.3.1. GLOBAL ERYTHROPOIETIN DRUGS CAPACITY (VOLUME) AND GROWTH RATE (%), (2017-2025)
    2.4. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025
    2.4.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND GROWTH RATE (%), (2017-2025)
    2.5. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    2.5.1. GLOBAL ERYTHROPOIETIN DRUGS CONSUMPTION (VOLUME) AND GROWTH RATE (%), (2017-2025)

    CHAPTER 3. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY DRUG CLASS, 2017-2025
    3.1. EPOETIN-ALFA
    3.2. EPOETIN-BETA
    3.3. DARBEPOETIN-ALFA
    3.4. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE BY DRUG CLASS, 2017-2025
    3.4.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY DRUG CLASS, 2017-2025
    3.4.2. EPOETIN-ALFA MARKET REVENUE AND GROWTH RATE, 2017-2025
    3.4.3. EPOETIN-BETA MARKET REVENUE AND GROWTH RATE, 2017-2025
    3.4.4. DARBEPOETIN-ALFA MARKET REVENUE AND GROWTH RATE, 2017-2025
    3.5. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION BY DRUG CLASS, 2017-2025
    3.5.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY DRUG CLASS, 2017-2025
    3.5.2. EPOETIN-ALFA MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    3.5.3. EPOETIN-BETA MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    3.5.4. DARBEPOETIN-ALFA MARKET PRODUCTION AND GROWTH RATE, 2017-2025

    CHAPTER 4. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY APPLICATION, 2017-2025
    4.1. CANCER
    4.2. RENAL DISEASE
    4.3. HEMATOLOGY
    4.4. NEUROLOGY
    4.5. OTHERS
    4.6. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE BY APPLICATION, 2017-2025
    4.6.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY APPLICATION, 2017-2025
    4.6.2. CANCER MARKET REVENUE AND GROWTH RATE, 2017-2025
    4.6.3. RENAL DISEASE MARKET REVENUE AND GROWTH RATE, 2017-2025
    4.6.4. HEMATOLOGY MARKET REVENUE AND GROWTH RATE, 2017-2025
    4.7. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION BY APPLICATION, 2017-2025
    4.7.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY APPLICATION, 2017-2025
    4.7.2. CANCER MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    4.7.3. RENAL DISEASE MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    4.7.4. HEMATOLOGY MARKET CONSUMPTION AND GROWTH RATE, 2017-2025

    CHAPTER 5. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY DRUG TYPE, 2017-2025
    5.1. BIOLOGICS
    5.2. BIOSIMILAR

    CHAPTER 6. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY DISTRIBUTION CHANNEL, 2017-2025
    6.1. HOSPITAL PHARMACY
    6.2. RETAIL PHARMACY
    6.3. ONLINE PHARMACY

    CHAPTER 7. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY REGION, 2017-2025
    7.1. NORTH AMERICA
    7.1.1. U.S.
    7.1.2. CANADA
    7.1.3. MEXICO
    7.2. EUROPE
    7.2.1. U.K.
    7.2.2. FRANCE
    7.2.3. GERMANY
    7.2.4. ITALY
    7.2.5. SPAIN
    7.2.6. REST OF EUROPE
    7.3. ASIA PACIFIC
    7.3.1. CHINA
    7.3.2. JAPAN
    7.3.3. INDIA
    7.3.4. KOREA
    7.3.5. REST OF APAC
    7.4. SOUTH AMERICA
    7.4.1. BRAZIL
    7.4.2. REST OF SOUTH AMERICA
    7.5. REST OF THE WORLD
    7.5.1. MIDDLE EAST
    7.5.2. AFRICA
    7.6. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE BY REGION, 2017-2025
    7.6.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY REGION, 2017-2025
    7.6.2. NORTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
    7.6.3. EUROPE MARKET REVENUE AND GROWTH RATE, 2017-2025
    7.6.4. ASIA PACIFIC MARKET REVENUE AND GROWTH RATE, 2017-2025
    7.6.5. SOUTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
    7.6.6. REST OF THE WORLD MARKET REVENUE AND GROWTH RATE, 2017-2025

    CHAPTER 8. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
    8.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
    8.1.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
    8.1.2. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
    8.1.3. NORTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
    8.1.4. EUROPE MARKET PRODUCTION AND CONSUMPTION, 2017-2025
    8.1.5. ASIA PACIFIC MARKET PRODUCTION AND CONSUMPTION, 2017-2025
    8.1.6. SOUTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
    8.1.7. REST OF THE WORLD MARKET PRODUCTION AND CONSUMPTION, 2017-2025

    CHAPTER 9. MARKET DETERMINANTS
    9.1. MARKET DRIVERS
    9.2. MARKET RESTRAINTS
    9.3. MARKET OPPORTUNITIES
    9.4. MARKET DETERMINANTS RADAR CHART

    CHAPTER 10. GLOBAL ERYTHROPOIETIN DRUGS MARKET COMPETITION BY MANUFACTURERS
    10.1. GLOBAL ERYTHROPOIETIN DRUGS PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
    10.1.1. GLOBAL ERYTHROPOIETIN DRUGS PRODUCTION (VOLUME) AND SHARE (%) BY MANUFACTURERS (2017-2025)
    10.2. GLOBAL ERYTHROPOIETIN DRUGS REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
    10.2.1. GLOBAL ERYTHROPOIETIN DRUGS REVENUE (MILLION USD) AND SHARE (%) BY MANUFACTURERS (2017-2025)
    10.3. ERYTHROPOIETIN DRUGS MARKET COMPETITIVE SITUATION AND TRENDS
    10.3.1. ERYTHROPOIETIN DRUGS MARKET SHARE (%) OF TOP 3 MANUFACTURERS
    10.3.2. ERYTHROPOIETIN DRUGS MARKET SHARE (%) OF TOP 5 MANUFACTURERS

    CHAPTER 11. GLOBAL ERYTHROPOIETIN DRUGS MANUFACTURERS ANALYSIS
    11.1. LG LIFE SCIENCES LIMITED
    11.1.1. BUSINESS OVERVIEW
    11.1.2. COMPANY BASIC INFORMATION
    11.1.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.1.4. LG LIFE SCIENCES LIMITED ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
    11.2. RANBAXY LABORATORIES LTD
    11.2.1. BUSINESS OVERVIEW
    11.2.2. COMPANY BASIC INFORMATION
    11.2.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.2.4. RANBAXY LABORATORIES LTD ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
    11.3. TEVA PHARMACEUTICAL INDUSTRIES LTD
    11.3.1. BUSINESS OVERVIEW
    11.3.2. COMPANY BASIC INFORMATION
    11.3.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.3.4. TEVA PHARMACEUTICAL INDUSTRIES LTD ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
    11.4. BIOCON LIMITED
    11.4.1. BUSINESS OVERVIEW
    11.4.2. COMPANY BASIC INFORMATION
    11.4.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.4.4. BIOCON LIMITED ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
    11.5. HOFFMANN-LA ROCHE AG
    11.5.1. BUSINESS OVERVIEW
    11.5.2. COMPANY BASIC INFORMATION
    11.5.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.5.4. HOFFMANN-LA ROCHE AG ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
    11.6. HOSPIRA INC.
    11.6.1. BUSINESS OVERVIEW
    11.6.2. COMPANY BASIC INFORMATION
    11.6.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.6.4. HOSPIRA INC. ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
    11.7. PFIZER INC.
    11.7.1. BUSINESS OVERVIEW
    11.7.2. COMPANY BASIC INFORMATION
    11.7.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.7.4. PFIZER INC. ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
    11.8. JOHNSON & JOHNSON LLC
    11.8.1. BUSINESS OVERVIEW
    11.8.2. COMPANY BASIC INFORMATION
    11.8.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.8.4. JOHNSON & JOHNSON LLC ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
    11.9. NOVARTIS INTERNATIONAL AG
    11.9.1. BUSINESS OVERVIEW
    11.9.2. COMPANY BASIC INFORMATION
    11.9.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.9.4. NOVARTIS INTERNATIONAL AG ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
    11.10. GLAXOSMITHKLINE PLC
    11.10.1. BUSINESS OVERVIEW
    11.10.2. COMPANY BASIC INFORMATION
    11.10.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
    11.10.4. GLAXOSMITHKLINE PLC ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN

    CHAPTER 12. ERYTHROPOIETIN DRUGS MARKET VALUE CHAIN ANALYSIS
    12.1. ERYTHROPOIETIN DRUGS INDUSTRIAL CHAIN ANALYSIS
    12.2. ERYTHROPOIETIN DRUGS KEY RAW MATERIALS ANALYSIS
    12.2.1. KEY RAW MATERIALS
    12.2.2. PRICE TREND OF KEY RAW MATERIALS
    12.2.3. KEY SUPPLIERS OF RAW MATERIALS
    12.3. CONSUMER ANALYSIS
    12.3.1. CONSUMER 1
    12.3.2. CONSUMER 2
    12.3.3. CONSUMER 3
    12.3.4. CONSUMER 4

    keyboard_arrow_up
  • • LG Life Sciences Limited
    • Ranbaxy Laboratories Ltd
    • Teva Pharmaceutical Industries Ltd
    • Biocon Limited
    • Hoffmann-La Roche AG
    • Hospira Inc.
    • Pfizer Inc.
    • Johnson & Johnson LLC
    • Novartis International AG.
    • Amgen Inc
    • GlaxoSmithKline plc
    • Merck & Co
    • Wockhardt Ltd.

    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What Information does this report contain?

• What was the market size of the Erythropoietin Drugs Market in 2018 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions and their comparative growth rate?
• Which technology is in trend and how would it evolve during the forecast period (2018 – 2025)?
• Which are the leading companies in the Erythropoietin Drugs Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

CLIENTS

SHARE YOUR CART